

Ongoing Regenerative Medicine Clinical Trials to Treat COVID-19 & Related Complications

Sponsors & Collaborators	Trial Countries	Phase	Anticipated Enrollment	Tech Type	Tech Sub-Type	Preliminary Results
Chongqing Public Health Medical Center; Chongqing Sidemu Biotechnology Technology	China	1/2	90	GMCT	NK Cell	n/a
Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital	China	1	100	GMCT	APC / Dendritic Cell	n/a
Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital	China	1/2	100	GMCT	APC / Dendritic Cell	n/a
Shanghai Public Health Clinical Center; R&D Kanglin Biotech	China	1	30	GMCT	NK Cell	n/a
Beijing 302 Hospital; Innovative Precision Medicine Group; Wuhan Huoshenshan Hospital; Tianjin Haihe Hospital; VCANBIO; Shenzhen Third People's Hospital	China	1	20	CT	MSCs	n/a
Beijing 302 Hospital; VCANBIO; Wuhan Huoshenshan Hospital; Tianjin Haihe Hospital; Shenzhen Third People's Hospital; Sun Yat-Sen University; Wuhan Union Hospital	China	1/2	60	CT	MSCs	n/a
Chinese Academy of Medical Sciences; The National Key Research and Development Program of China	China	1/2	60	CT	MSCs	Here
Nanjing Second Hospital	China	1	9	CT	MSCs	n/a
Stem Cells Arabia	Jordan	1	5	CT	MSCs	n/a
Capricor	US	EA / CU	n/a	CT	Cardiosphere-derived cells	n/a
Belfast Health and Social Care Trust; Queen's University, Belfast; Northern Ireland Clinical Trials Unit; NHS Blood and Transplant	UK	1/2	75	CT	MSCs	n/a
Huangshi Hospital of Traditional Chinese Medicine	China	1	18	CT	MSCs	n/a
Renmin Hospital of Wuhan University; Beijing SH Bio-Tech Corporation; Utooth Biological Technology Co.	China	1/2	20	CT	MSCs	n/a
Pluristem	Israel	EA / CU	7	CT	Other	Here
Chinese Academy of Sciences; Beijing YouAn Hospital	China	1/2	9	CT	Other stem cells	n/a
Healios	Japan	2	30	CT	Other stem cells	n/a

EA / CU – expanded access / compassionate use; CT = cell therapy; GMCT = gene-modified or cell-based immunotherapy; MSCs = mesenchymal stem cells; APC = antigen presenting cells; NK = natural killer

This dataset only includes those trials that are active, interventional, therapeutic, Phase 1-3 trials. Therapeutic candidates used under expanded access or compassionate use programs may not be included if not administered via a registered clinical trial.

Updated: April 14, 2020